Compare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIAN HEALTHCARE vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIAN HEALTHCARE VENUS REMEDIES CIAN HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x - 6.4 - View Chart
P/BV x 1.1 1.4 79.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 CIAN HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CIAN HEALTHCARE
Mar-20
VENUS REMEDIES
Mar-21
CIAN HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs63314 20.0%   
Low Rs1222 55.2%   
Sales per share (Unadj.) Rs24.4444.2 5.5%  
Earnings per share (Unadj.) Rs-1.650.1 -3.2%  
Cash flow per share (Unadj.) Rs0.378.6 0.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs24.9313.2 8.0%  
Shares outstanding (eoy) m23.3612.34 189.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.50.4 406.1%   
Avg P/E ratio x-23.23.4 -689.8%  
P/CF ratio (eoy) x132.82.1 6,209.6%  
Price / Book Value ratio x1.50.5 281.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m8782,075 42.3%   
No. of employees `000NANA-   
Total wages/salary Rs m40460 8.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m5715,481 10.4%  
Other income Rs m9196 4.4%   
Total revenues Rs m5805,678 10.2%   
Gross profit Rs m73772 9.4%  
Depreciation Rs m44353 12.6%   
Interest Rs m72130 55.4%   
Profit before tax Rs m-35486 -7.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3-132 -2.0%   
Profit after tax Rs m-38618 -6.1%  
Gross profit margin %12.714.1 90.5%  
Effective tax rate %-7.5-27.2 27.4%   
Net profit margin %-6.611.3 -58.9%  
BALANCE SHEET DATA
Current assets Rs m7692,316 33.2%   
Current liabilities Rs m500974 51.3%   
Net working cap to sales %47.024.5 192.1%  
Current ratio x1.52.4 64.6%  
Inventory Days Days6525 261.6%  
Debtors Days Days128213 59.9%  
Net fixed assets Rs m7963,243 24.5%   
Share capital Rs m234123 189.3%   
"Free" reserves Rs m3483,742 9.3%   
Net worth Rs m5823,865 15.1%   
Long term debt Rs m458468 97.9%   
Total assets Rs m1,5645,559 28.1%  
Interest coverage x0.54.7 10.8%   
Debt to equity ratio x0.80.1 650.2%  
Sales to assets ratio x0.41.0 37.0%   
Return on assets %2.213.5 16.3%  
Return on equity %-6.516.0 -40.7%  
Return on capital %3.514.2 25.0%  
Exports to sales %9.00-   
Imports to sales %0.10-   
Exports (fob) Rs m52NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m520-   
Fx outflow Rs m00-   
Net fx Rs m510-   
CASH FLOW
From Operations Rs m-841,326 -6.3%  
From Investments Rs m-274557 -49.3%  
From Financial Activity Rs m369-1,622 -22.7%  
Net Cashflow Rs m10269 3.8%  

Share Holding

Indian Promoters % 70.9 40.8 173.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 0.0 0.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 59.2 49.2%  
Shareholders   385 18,231 2.1%  
Pledged promoter(s) holding % 20.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIAN HEALTHCARE With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

SGX Nifty Down 67 Points; Indicates Negative Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a negative note today. At 8:00 am, it was trading down by 67 points, or 0.4% lower at 18,207 levels.

Related Views on News

VENUS REMEDIES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 2, 2021 | Updated on Nov 2, 2021

Here's an analysis of the annual report of VENUS REMEDIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Looking for Consistent Compounding Stocks? Here's a Watchlist for You(Views On News)

Jan 6, 2022

These companies have generated mind boggling returns for investors over the years.

My Best Sectors for 2022(Fast Profits Daily)

Jan 4, 2022

My top 2 sectors for 2022 might surprise you.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIAN HEALTHCARE SHARE PRICE


Jan 14, 2022 (Close)

TRACK CIAN HEALTHCARE

  • Track your investment in CIAN HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CIAN HEALTHCARE

CIAN HEALTHCARE 5-YR ANALYSIS

COMPARE CIAN HEALTHCARE WITH

MARKET STATS